Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma

Ploussard, Guillaume; Xylinas, Évanguelos; Lotan, Yair; Novara, Giacomo; Margulis, Vitaly; Rouprêt, Morgan; Matsumoto, Kazumasa; Karakiewicz, Pierre I.; Montorsi, Francesco; Remzi, M.; Seitz, Christian; Scherr, Douglas S.; Kapoor, Anil; Fairey, Adrian; Rendon, Ricardo; Izawa, Jonathan I.; Black, Peter C.; Lacombe, Louis; Shariat, Shahrokh F.; Kassouf, Wassim

doi:10.1016/j.eururo.2014.08.003

Cited by 83 publications

(76 citation statements)

References 26 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,17,18,21,42 Data from the current study similarly noted that the most important gains in survival estimates were among patients with aggressive disease. In particular, patients with worse prognostic features had a higher increase in CDFS based on actual time survived (Table 3 and Fig.…”

Section: Discussionsupporting

confidence: 67%

Curative Surgical Resection of Adrenocortical Carcinoma

et al. 2017

View full text Add to dashboard Cite

Objective To evaluate conditional disease-free survival (CDFS) for patients who underwent curative intent surgery for adrenocortical carcinoma (ACC). Background ACC is a rare but aggressive tumor. Survival estimates are usually reported as survival from the time of surgery. CDFS estimates may be more clinically relevant by accounting for the changing likelihood of disease-free survival (DFS) according to time elapsed after surgery. Methods CDFS was assessed using a multi-institutional cohort of patients. Cox proportional hazards models were used to evaluate factors associated with DFS. Three-year CDFS (CDFS3) estimates at “x” year after surgery were calculated as follows: CDFS3=DFS(x+3)/DFS(x). Results One hundred ninety-two patients were included in the study cohort; median patient age was 52 years. On presentation, 36% of patients had a functional tumor and median size was 11.5 cm. Most patients underwent R0 resection (75%) and 9% had N1 disease. Overall 1-, 3-, and 5-year DFS was 59%, 34%, and 22%, respectively. Using CDFS estimates, the probability of remaining disease free for an additional 3 years given that the patient had survived without disease at 1, 3, and 5 years, was 43%, 53%, and 70%, respectively. Patients with less favorable prognosis at baseline demonstrated the greatest increase in CDFS3 over time (eg, capsular invasion: 28%–88%, Δ60% vs no capsular invasion: 51%–87%, Δ36%). Conclusions DFS estimates for patients with ACC improved dramatically over time, in particular among patients with initial worse prognoses. CDFS estimates may provide more clinically relevant information about the changing likelihood of DFS over time.

show abstract

Section: Discussionsupporting

confidence: 67%

Curative Surgical Resection of Adrenocortical Carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The risk of recurrence and death evolves during the followup period after surgery [80]. Stringent follow-up (Table 5) is mandatory to detect metachronous bladder tumours, local recurrence, and distant metastases.…”

Section: Follow-upmentioning

confidence: 99%

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…Two-years cDFS relative to each timepoint was then obtained by dividing the survival rate at each of the 24 + timepoints months by the survival rate at the baseline timepoints. In other words, cDFS (2y|timepoint)=S(timepoint+24)/S(timepoint) according to previous studies [8] [9] [10]. Comparison of changes in cDFS was further performed after stratification according to the most clinically relevant variables at univariate analysis.…”

Section: Methodsmentioning

confidence: 99%

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma

Santini

Santoni

Conti³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

PURPOSEWe retrospectively analyzed the risk of recurrence and conditional Disease-Free Survival (cDFS) in 63 patients with complete remission during treatment with tirosin kinase inhibitor (TKI), alone or with local treatment in metastatic renal cell carcinoma.RESULTS37% patients achieve CR with TKI alone, while 63% with additional loco-regional treatments. 49% patients recurred after CR, with a median Disease free survival of 28.2 months. Patients treated with multimodal approaches present lower rate of recurrence (40% vs 61%) and longer Disease free survival compared to patient treated with TKI alone (16.5 vs 41.9 months, p=0.039).Furthermore the rate of recurrence was higher in patients with brain (88%), pancreatic (71%) and bone metastasis (50%). Patients who continued TKI therapy after complete response had a longer disease free survival than patients who stopped therapy, although the difference was not significant (42.1 vs 25.1 months, p=0.254). 2y-cDFS was better in patients treated with multimodal treatment and who continued TKIs than the other patient arms.CONCLUSIONSThe prognostic value of CR depends on the site where was obtained and how was obtained (with or without locoregional treatment). Cessation of TKI should be carefully considered in complete responder patients.

show abstract

Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma

Cited by 83 publications

References 26 publications

Curative Surgical Resection of Adrenocortical Carcinoma

Curative Surgical Resection of Adrenocortical Carcinoma

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma

Contact Info

Product

Resources

About